A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 3, 2001, Pages 93-101

  Chiou, W L ^a   Chung, S M ^a   Wu, T C ^a   Ma, C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Caco 2 cells; Efflux transporters; Gastrointestinal absorption; Intestinal permeability; Oral bioavailability; P glycoprotein

Indexed keywords

CELIPROLOL; CYCLOSPORIN; DIGOXIN; ETOPOSIDE; FELODIPINE; FEXOFENADINE; FUROSEMIDE; GLYCOPROTEIN P; INDINAVIR; LOSARTAN; NADOLOL; PACLITAXEL; PAFENOLOL; PROPRANOLOL; QUINIDINE; RITONAVIR; SAQUINAVIR; TACROLIMUS; TALINOLOL; VERAPAMIL;

ANIMAL MODEL; APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG PENETRATION; DRUG SCREENING; DRUG TRANSPORT; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MEDICAL LITERATURE; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PRESCRIPTION; URINARY EXCRETION;

EID: 0035098868     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39093     Document Type: Article

References (70)

1. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
2. Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport
3. Drug interaction between St. John's Wort and cyclosporine
4. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
5. Design and optimization of dosage regimens; pharmacokinetics data
6. Method for increasing bioavailability of oral pharmaceutical compositions
7. Celiprolol: Pharmacokinetics and duration of pharmacodynamic activity
8. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption
9. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats
10. The rate and extent of oral bioavailability vs. The rate and extent of oral absorption: Clarification and recommendation of terminology
11. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
12. Commentary: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs
13. Similarity in the linear and non-linear oral absorption of drugs between human and rat
14. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol
15. Potential overestimation of the role of gastrointestinal metabolism and P-glycoprotein mediated efflux in contributing to low bioavailability of drugs in humans
16. Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model
17. Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model
18. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin
19. Dose-effect and kinetic-dynamic relationship of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans
20. An in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugs
21. Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single oral and intravenous doses
22. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient
23. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum
24. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: In vitro-in vivo correlation
25. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
26. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
27. Digoxin bioavailability during quinidine administration
28. Molecular and physical mechanisms of first-pass extraction
29. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4
30. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
31. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
32. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption
33. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's Wort (Hypericum perforatum)
34. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: Mediation of secretion by multiple transporters including P-glycoprotein
35. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
36. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
37. Erythromycin breath test: Reply
38. Dose-dependent bioavailability of propranolol
39. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
40. Pharmacokinetics and pharmacodynamics of high dose furosemide in patients with chronic renal failure or nephrotic syndrome
41. Mdr1 limits CYP3 A metabolism in vivo
42. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism
43. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption
44. Evaluation of an accelerated Caco-2 cell permeability model
45. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
46. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
47. Effect of dose on bioavailability of oral digoxin
48. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active non-peptide angiotensin II receptor antagonist, in humans
49. Effect of quinidine on digoxin bioavailability
50. Indinavir concentrations and St John's Wort
51. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers
52. Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man
53. Antiarrhythmic; drugs
54. Increased drug delivery to the brain by P-glycoprotein inhibition
55. Human P-glycoprotein transports cyclosporin A and FK506
56. Pharmacokinetics of nadolol in healthy subjects
57. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
58. Tolerability and pharmacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor
59. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers
60. Grapefruit juice activates P-glycoprotein-mediated drug transport
61. P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound
62. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
63. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier
64. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
65. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
66. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo
67. Intestinal absorption of a beta-adrenergic blocking agent nadolol. I. Comparison of absorption behavior of nadolol with those of other beta-blocking agents in rats
68. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr 1 a knockout mice
69. An integrated model for determining causes of poor oral drug absorption